New EU Filings Include First-Of-Its-Kind MS Drug Tolebrutinib & HIV Prophylaxis Lenacapavir

 
• By Neena Brizmohun

Several new drugs that are yet to be approved anywhere in the world are now under review by the European Medicines Agency for potential pan-EU marketing authorization.

Neurodegenerative disease concept 3d illustration
Tolebrutinib is an oral, brain-penetrant and bioactive BTK inhibitor for treating multiple sclerosis (Shutterstock)

More from EU CHMP

More from Geography